A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
Phase of Trial: Phase II/III
Latest Information Update: 30 Aug 2019
Price : $35 *
At a glance
- Drugs Tozuleristide (Primary)
- Indications CNS cancer
- Focus Diagnostic use; Registrational
- Sponsors Blaze Bioscience
- 28 Nov 2018 According to a Blaze Bioscience media release, the company announced the initiation of this pivotal study and that they have enrolled the first patient at Seattle Childrens Hospital.
- 27 Nov 2018 Planned End Date changed from 1 Nov 2019 to 1 Jul 2020.
- 27 Nov 2018 Planned primary completion date changed from 1 Aug 2019 to 1 Apr 2020.